News

Fierce Biotech2d
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
Neurofibromatosis Type 1 Market Set To Witness Significant Growth During The Study Period (2020–2034) Driven By Advances In Treatment | Delveinsight
The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical ...
Fierce Pharma6d
Merck KGaA cites Trump tariffs, funding cuts as it scales back 2025 contracting forecast
As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...
Merck & Co., Inc. (MRK): One of the Best Dividend Growth Stocks with High Yields
We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...
Fierce Pharma6d
Riding its Peloton buyout, Merck rolls to third FDA nod for potential blockbuster Welireg
Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...
Life Science Business Underpins Our Narrow Moat Rating
We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...